Bayer continues to Profit from Yaz

Bayer continues to profit from its dangerous combination oral contraceptive, Yaz. In its latest financial report for fiscal year 2009 Bayer reported that the YAZ line generated sales of 1.3 billion euros ($1.8 billion), up 4.6 percent compared to the year before.

Quarterly revenue from the company's YAZ family of oral contraceptives was unchanged at 314 million euros ($426 million).

Bayer's fourth-quarter revenue from its HealthCare division reached 4.2 billion euros ($5.7 billion), up from last year's fourth quarter.

The HealthCare unit revenues rose 3.8 percent to 16 billion euros ($21.7 billion), due to growth "particularly in the emerging markets." Sales of pharmaceutical products were up 4.4 percent to 10.5 billion euros ($14.3 billion).

The Company as a whole generated revenue for 2009 of 31.2 billion euros ($42.4 billion), down 5.3 percent compared to 2008.

The flattening out of the increase in revenues from Yaz is a hopeful sign that consumers (and their physicians) are getting the message about the Dangers of Yaz.

If you or or a loved one have been injured by Yaz, Yasmin or Ocella contact us free of charge at our toll-free number (888) 841-9623.